Scott, verdiperstat was developed by AstraZeneca, Early trials were Parkinson's. The 2015 the 59 patient trial was for MSA. Biohaven licensed it in 2018. They ran a 52 patient trial in MSA. In 2019 Biohaven ran a 336 patient trial in MSA which failed. They gave up on MSA and only then went for ALS.
MOA was reduction of an enzyme that caused inflammation, but they did succeed in reducing A-Syn. Spooky thing is that they had success in reducing A-Syn, but still failed the p3 MSA trial. 434 reduces A-Syn through a different MOA, yet we expect our drug to succeed. Why?
WTF !!!, page-45
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $1.937K | 645.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 77 | 96988980 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 655773 | 2 |
View Market Depth
| Last trade - 10.00am 15/11/2024 (20 minute delay) ? |
| ATH (ASX) Chart |